Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-04-07 Board/Management Inform…
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment and resignation of senior management personnel, specifically the appointment of Mr. Anurag Mantri as President and the resignation of Mr. V.S. Mani as Executive Director & Global CFO. It references compliance with SEBI Listing Regulations and includes details about the individuals' profiles and terms. There are no financial statements, earnings data, or report publications. The content clearly pertains to changes in senior management positions, fitting the category of Board/Management Information (MANG). The document length is about 4964 characters, sufficient for a detailed announcement but not a full report.
2025-04-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product by Glenmark Pharmaceuticals Inc., USA. It includes details about the product, market data, and a quote from a company executive. There is no financial data, regulatory filing references, or detailed report content. The document is a corporate announcement related to product launch, not a financial report, regulatory filing, or management report. Therefore, it fits best under the category of a general regulatory announcement or corporate news update, which corresponds to Regulatory Filings (RNS).
2025-04-01 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information that a listed company must disclose to stock exchanges. The content describes the planned closure of a manufacturing facility by a subsidiary, including details such as turnover, net worth, and reasons for closure. It is an announcement of a corporate event rather than a financial report or detailed analysis. The document is relatively short (3336 characters) and serves as a regulatory announcement to stock exchanges rather than a full report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-28 English
Copy of Newspaper Publication
Regulatory Filings
2025-03-27 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a postal ballot sent to shareholders of Glenmark Pharmaceuticals Limited. It includes resolutions for appointment and reappointment of independent directors and payment of commission to non-executive directors. The document references compliance with SEBI Listing Regulations and the Companies Act, 2013, and details the voting process including remote e-voting dates and procedures. It is not a report of voting results but the notice and explanatory statement for the postal ballot itself. The content is focused on governance matters, specifically board appointments and remuneration-related resolutions. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or ballots. The document is lengthy (15,000 characters) and contains substantive information, not just an announcement or a brief notice. Therefore, the appropriate classification is PSI with high confidence.
2025-03-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific ophthalmic solution product. It is addressed to stock exchanges and corporate services, requesting the announcement to be taken on record. The content focuses on the approval and product launch, with no financial statements, regulatory certifications, or detailed financial data. The document length is about 5,211 characters, which is relatively short and primarily an announcement rather than a detailed report. There is no indication of it being an annual report, earnings release, or any other detailed financial or regulatory filing. Therefore, this document fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for miscellaneous filings that do not fit other specific categories.
2025-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.